August 12, 2003
Paula Braitstein and colleagues at the B.C. Centre for Excellence in HIV/AIDS studied the effect of HCV on CD4+ cell count changes among HAART users by reviewing records in the centre's database, collected between August 1996 and July 2000. Information was analysed on 1,416 people with HIV/AIDS (PHAs) who had never previously taken HAART but began to do so during the study period. The research team also found results of blood tests for antibodies against HCV in a subset of 552 subjects as follows:
A factor the researchers took into account when later analysing the data was adherence. The research team assessed adherence in an indirect way. They checked pharmacy databases to determine whether subjects had their prescriptions filled on a regular basis. According to previous studies, the ability to fill prescriptions on a regular basis is linked to a high degree of adherence.
Before starting therapy, the profile of the 235 PHAs who were also HCV positive was as follows:
Among subjects positive only for HIV and whom researchers judged to be at least 95% adherent, the average increase in the CD4+ cell count after the first 1½ years of treatment was 230 extra cells. Among subjects who were less than 95% adherent, the increase was 190 extra cells.
Among co-infected subjects, results of treatment were not as promising. After 1½ years of treatment, in the group whose adherence was at least 95% there was an increase of 120 extra CD4+ cells. In subjects whose adherence was less than 95%, there was an increase of only 50 extra cells.
According to the research team, these results show that after adjusting for adherence, HCV has a powerful effect on the ability of HAART to affect the immune system. It is not clear why HCV infection might have this effect. One possibility is that HCV affects the liver's ability to properly process drugs (such as protease inhibitors and non-nukes), and so levels of these drugs in the blood are not as high as they should be. But this theory needs to be tested and confirmed. The fact that the response to HAART was worse in co-infected people raises questions about the timing for initiating HIV therapy in this population. Perhaps HAART would be more effective in HCV co-infected people if taken earlier in the course of HIV disease, when their CD4+ counts are higher? Again, this is another idea that requires further study. Overall, the Vancouver study confirms results by research teams in the European Union and lays the foundation for future studies in the area of HIV/HCV co-infection.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017|
|'Caring at Its Essence': HIV Nurses Recall Pivotal Moments With Patients|
|PrEP Prescriptions Rise Sharply, but Unequally, in New York City|
|How to Reverse Implicit Bias in HIV Care: 6 Steps to Take Today|
|In Their Words: Burdens of HIV Nursing Include Lack of Respect and Resources|
|Conversations With Federal HIV Leaders From the 2017 U.S. Conference on AIDS|